- Home
- IONS vs NXST Comparison
IONS vs NXST Comparison
Compare IONS & NXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- NXST
- Stock Information
- Founded
- IONS 1989
- NXST 1996
- Country
- IONS United States
- NXST United States
- Employees
- IONS N/A
- NXST N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- NXST Broadcasting
- Sector
- IONS Health Care
- NXST Industrials
- Exchange
- IONS Nasdaq
- NXST Nasdaq
- Market Cap
- IONS 6.8B
- NXST 6.2B
- IPO Year
- IONS 1991
- NXST 2003
- Fundamental
- Price
- IONS $61.23
- NXST $208.27
- Analyst Decision
- IONS Buy
- NXST Strong Buy
- Analyst Count
- IONS 17
- NXST 7
- Target Price
- IONS $67.88
- NXST $221.43
- AVG Volume (30 Days)
- IONS 3.1M
- NXST 446.4K
- Earning Date
- IONS 07-30-2025
- NXST 08-07-2025
- Dividend Yield
- IONS N/A
- NXST 3.59%
- EPS Growth
- IONS N/A
- NXST 53.49
- EPS
- IONS N/A
- NXST 19.36
- Revenue
- IONS $944,050,000.00
- NXST $5,316,000,000.00
- Revenue This Year
- IONS $24.30
- NXST N/A
- Revenue Next Year
- IONS $7.39
- NXST $10.28
- P/E Ratio
- IONS N/A
- NXST $10.72
- Revenue Growth
- IONS 16.05
- NXST 6.55
- 52 Week Low
- IONS $23.95
- NXST $141.66
- 52 Week High
- IONS $62.08
- NXST $223.36
- Technical
- Relative Strength Index (RSI)
- IONS 83.44
- NXST 61.70
- Support Level
- IONS $42.13
- NXST $200.77
- Resistance Level
- IONS $62.08
- NXST $207.49
- Average True Range (ATR)
- IONS 2.11
- NXST 5.75
- MACD
- IONS 2.09
- NXST -0.57
- Stochastic Oscillator
- IONS 95.83
- NXST 37.02
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About NXST Nexstar Media Group Inc.
Nexstar is the largest television station owner-operator in the United States with over 200 stations in 116 markets, reaching 220 million people. Of its 200 stations, 155 are affiliated with the four national broadcast networks: CBS, Fox, NBC, and ABC. Pending approval, Nexstar's merger with Tegna would bring Nexstar's station total to 259 in 133 markets, reaching 80% of the US population. Nexstar also owns NewsNation (formerly WGN), a cable news network, 75% of the fifth national broadcaster, the CW, and a 31% stake in Food Network and Cooking Channel.